Valentina V. Noskova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valentina V. Noskova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey N. Khrabrikov
Kirov State Medical University
4 shared publications B. Casslén
1 shared publication- Bertil Casslén
Department of Obstetrics & Gynaecology, Lund University, Skåne University Hospital Lund, Lund, SE 221 85, Sweden
1 shared publication C. Andersson
1 shared publicationE. Henic
1 shared publication- Gunilla Høyer-Hansen
The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaloes Vej 5, Building 3, 3rd Floor, 2200 Copenhagen, Denmark
1 shared publication
Latest Publications
- 30 September 2025
- Published by LLC Science and Innovations in Saratov Journal of Medical Scientific Research
- Vol. 21 (3)
Auditory steady-state evoked potentials in sensorineural hearing loss and normal auditory function
Objective: to evaluate the correlation between psychoacoustic hearing thresholds and ASSR (Auditory Steady-State Response) thresholds in patients with sensorineural hearing loss (SNHL) and in otologically healthy subjects. Material and methods. Auditory function was studied in 130 people grouped into 3 groups: group 1 consisted of patients with chronic SNHL (n=50), group 2 - patients with acute SNHL (n=50), group 3 - otologically healthy subjects (n=30). Thresholds were compared when registering tonal threshold audiometry and when registering auditory stationary evoked potentials. Results. The average difference between psychoacoustic hearing thresholds and ASSR thresholds at 4 speech frequencies in patients with SNHL in the right ear was 15 dB normal hearing threshold (NHT; p=0.005), in the left ear- 14.4 dB NHT (p=0.005), with a minimum difference of 12.3±5.9 dB NHT at 4000 Hz in patients with chronic SNHL in the right ear (p<0.001), with a maximum difference of 18.4±8.2 dB NHT at a frequency of 2000 Hz in patients with acute SNHL in the left ear (p=0.005). In otologically healthy subjects, the average difference between psychoacoustic hearing thresholds and ASR thresholds at 4 speech frequencies in the right ear was 10 dB NHT, in the left ear- 11.2 dB NHT. The minimum threshold difference was detected at a frequency of 4000 Hz in the right ear (6.5±1.6dB NHT; p<0.001), the maximum at a frequency of 500 Hz in the right ear (14.8±5.8 dB NHT). In patients with SNHL, the correlation coefficient ranged from 0.81 to 0.94 (p<0.001) when registering the tonal threshold audiometry and ASSR test. In otologically healthy subjects, the correlation closeness on the Chaddock scale ranged from 0.76 to 0.96 (p<0.001). Conclusion. The obtained values demonstrate a significant strong correlation between psychoacoustic hearing thresholds and ASSR thresholds.
- 30 September 2025
- Published by LLC Science and Innovations in Saratov Journal of Medical Scientific Research
- Vol. 21 (3)
Auditory steady-state evoked potentials in sensorineural hearing loss and normal auditory function
Objective: to evaluate the correlation between psychoacoustic hearing thresholds and ASSR (Auditory Steady-State Response) thresholds in patients with sensorineural hearing loss (SNHL) and in otologically healthy subjects. Material and methods. Auditory function was studied in 130 people grouped into 3 groups: group 1 consisted of patients with chronic SNHL (n=50), group 2 - patients with acute SNHL (n=50), group 3 - otologically healthy subjects (n=30). Thresholds were compared when registering tonal threshold audiometry and when registering auditory stationary evoked potentials. Results. The average difference between psychoacoustic hearing thresholds and ASSR thresholds at 4 speech frequencies in patients with SNHL in the right ear was 15 dB normal hearing threshold (NHT; p=0.005), in the left ear- 14.4 dB NHT (p=0.005), with a minimum difference of 12.3±5.9 dB NHT at 4000 Hz in patients with chronic SNHL in the right ear (p<0.001), with a maximum difference of 18.4±8.2 dB NHT at a frequency of 2000 Hz in patients with acute SNHL in the left ear (p=0.005). In otologically healthy subjects, the average difference between psychoacoustic hearing thresholds and ASR thresholds at 4 speech frequencies in the right ear was 10 dB NHT, in the left ear- 11.2 dB NHT. The minimum threshold difference was detected at a frequency of 4000 Hz in the right ear (6.5±1.6dB NHT; p<0.001), the maximum at a frequency of 500 Hz in the right ear (14.8±5.8 dB NHT). In patients with SNHL, the correlation coefficient ranged from 0.81 to 0.94 (p<0.001) when registering the tonal threshold audiometry and ASSR test. In otologically healthy subjects, the correlation closeness on the Chaddock scale ranged from 0.76 to 0.96 (p<0.001). Conclusion. The obtained values demonstrate a significant strong correlation between psychoacoustic hearing thresholds and ASSR thresholds.
- 18 June 2025
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 90 (3) , 13-18
Correlation between endothelial dysfunction and sensorineural hearing loss
Objective. To investigate the characteristics of blood markers of endothelial dysfunction (ED) in patients with sensorineural hearing loss (SNHL) and in normally hearing people, to evaluate the correlation of the data obtained with SNHL degree based on the results of tonal threshold audiometry in the studied groups. Material and methods. Auditory function was studied in 94 people, including patients with chronic CHT (n=32), patients with acute CHT (n=32), and normally hearing subjects (n=30). Hearing assessment was carried out by recording tonal threshold audiometry, laboratory parameters were assessed by enzyme immunoassay (ELISA) and the biochemical method. Statistical processing was carried out using the Microsoft Excel 13 software package. Results. The study of biomarkers of endothelial dysfunction revealed that SNHL is characterized by impaired motor and adhesive function of vascular endothelium. Acute SNHL is more often characterized by an increase in the blood serum of the marker of vasospasm, endothelin-1 (ET-1), with the highest values (more than 0.5 pg/ml) detected in grade I and III hearing loss. On the contrary, chronic SNHL is characterized by an increase in blood serum markers of vascular endothelial adhesion disorders, namely fibrinogen and vascular endothelial adhesion molecules-1 (VCAM-1). Moreover, the highest values (more than 60 ng/ml) of the latter are found in grade II and III chronic SNHL.
- 18 June 2025
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 90 (3) , 13-18
Correlation between endothelial dysfunction and sensorineural hearing loss
Objective. To investigate the characteristics of blood markers of endothelial dysfunction (ED) in patients with sensorineural hearing loss (SNHL) and in normally hearing people, to evaluate the correlation of the data obtained with SNHL degree based on the results of tonal threshold audiometry in the studied groups. Material and methods. Auditory function was studied in 94 people, including patients with chronic CHT (n=32), patients with acute CHT (n=32), and normally hearing subjects (n=30). Hearing assessment was carried out by recording tonal threshold audiometry, laboratory parameters were assessed by enzyme immunoassay (ELISA) and the biochemical method. Statistical processing was carried out using the Microsoft Excel 13 software package. Results. The study of biomarkers of endothelial dysfunction revealed that SNHL is characterized by impaired motor and adhesive function of vascular endothelium. Acute SNHL is more often characterized by an increase in the blood serum of the marker of vasospasm, endothelin-1 (ET-1), with the highest values (more than 0.5 pg/ml) detected in grade I and III hearing loss. On the contrary, chronic SNHL is characterized by an increase in blood serum markers of vascular endothelial adhesion disorders, namely fibrinogen and vascular endothelial adhesion molecules-1 (VCAM-1). Moreover, the highest values (more than 60 ng/ml) of the latter are found in grade II and III chronic SNHL.
- 1 January 2025
- Published by LLC Polyforum Group in Russian Otorhinolaryngology
- Vol. 24 (1)
Melanoma in otolaryngologist practice
Introduction. Melanoma is a malignant tumor that arises from melanocytes that produce melanin. The tumor has a neuroectodermal nature, it is found in any organs and tissues. The prevalence of melanoma in the Russian Federation in 2022 was 72.7 people per 100,000 population, with 79.6% of cases of melanoma detected in stages I–II; and 19.2% of cases, in stages III–IV. Men and women get sick almost equally often. The average age observed for melanoma is 58.7 years. Clinical diagnosis of melanoma of the mucous membranes is difficult since the tumor may be asymptomatic or disguised as other chronic non-tumor diseases. The duration of the disease ranges from several months to 3–5 years. It depends primarily on the stage of the disease and the metastasis of the tumor. The mortality rate in melanoma is 2.8 and 7.5% in the 1st year after diagnosis. Objective. To present clinical observations of melanoma in the practice of an otorhinolaryngologist as a rare malignant tumor. Conclusions. It is necessary to maintain oncological alertness in cases of long-term inflammatory diseases of the ear, nasal cavity and paranasal sinuses. A clear diagnostic algorithm for managing a patient with suspected neoplasms and an integrated approach to the problem will increase the frequency of pathology detection before significant complications develop, speed up diagnosis, reduce the risk of diagnostic errors, and increase the patient’s chance of a favorable outcome of subsequent treatment.
- 1 January 2025
- Published by LLC Polyforum Group in Russian Otorhinolaryngology
- Vol. 24 (1)
Melanoma in otolaryngologist practice
Introduction. Melanoma is a malignant tumor that arises from melanocytes that produce melanin. The tumor has a neuroectodermal nature, it is found in any organs and tissues. The prevalence of melanoma in the Russian Federation in 2022 was 72.7 people per 100,000 population, with 79.6% of cases of melanoma detected in stages I–II; and 19.2% of cases, in stages III–IV. Men and women get sick almost equally often. The average age observed for melanoma is 58.7 years. Clinical diagnosis of melanoma of the mucous membranes is difficult since the tumor may be asymptomatic or disguised as other chronic non-tumor diseases. The duration of the disease ranges from several months to 3–5 years. It depends primarily on the stage of the disease and the metastasis of the tumor. The mortality rate in melanoma is 2.8 and 7.5% in the 1st year after diagnosis. Objective. To present clinical observations of melanoma in the practice of an otorhinolaryngologist as a rare malignant tumor. Conclusions. It is necessary to maintain oncological alertness in cases of long-term inflammatory diseases of the ear, nasal cavity and paranasal sinuses. A clear diagnostic algorithm for managing a patient with suspected neoplasms and an integrated approach to the problem will increase the frequency of pathology detection before significant complications develop, speed up diagnosis, reduce the risk of diagnostic errors, and increase the patient’s chance of a favorable outcome of subsequent treatment.
- 20 March 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 89 (1) , 21-27
Endothelial dysfunction as a pathogenetic factor of sensorineural hearing loss
Chronic sensorineural hearing loss (SNHL) is a common disease that leads to disability of the population. Despite the many reports devoted to SNHL, the question of the pathogenesis of the disease is still open. Many researchers consider the development of SNHL as a manifestation of microangiopathy. The mechanism of development of microangiopathy in SNHL is multifactorial, but most researchers agree that endothelial dysfunction (ED) triggers a complex of pathological changes in the vessels of the inner ear. Objective. Review of the results of scientific research in recent years on the problem of etiopathogenesis of sensorineural hearing loss from the perspective of endothelial dysfunction in the formation of auditory disorders.
- 20 March 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 89 (1) , 21-27
Endothelial dysfunction as a pathogenetic factor of sensorineural hearing loss
Chronic sensorineural hearing loss (SNHL) is a common disease that leads to disability of the population. Despite the many reports devoted to SNHL, the question of the pathogenesis of the disease is still open. Many researchers consider the development of SNHL as a manifestation of microangiopathy. The mechanism of development of microangiopathy in SNHL is multifactorial, but most researchers agree that endothelial dysfunction (ED) triggers a complex of pathological changes in the vessels of the inner ear. Objective. Review of the results of scientific research in recent years on the problem of etiopathogenesis of sensorineural hearing loss from the perspective of endothelial dysfunction in the formation of auditory disorders.
- 1 October 2006
- Published by Wiley in Journal of Thrombosis and Haemostasis
- Vol. 4 (s1) , 76
ID: 280 Estradiol inhibits EGF-induced mobilization of uPAR from detergent insoluble domains in ERa negative, GPR30 positive ovarian cancer cells.
- 1 October 2006
- Published by Wiley in Journal of Thrombosis and Haemostasis
- Vol. 4 (s1) , 76
ID: 280 Estradiol inhibits EGF-induced mobilization of uPAR from detergent insoluble domains in ERa negative, GPR30 positive ovarian cancer cells.
- Open Access
- 29 June 2006
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 12 (8) , 497-503
Endometrial TIMP-4 mRNA is expressed in the stroma, while TIMP-4 protein accumulates in the epithelium and is released to the uterine fluid
We have previously reported that endometrial mRNA expression of both tissue inhibitors of metalloproteinase-4 (TIMP-4) and matrix metalloproteinase-26 (MMP-26) peaks in the early secretory phase, which implies a role in implantation. The objective of this study was to compare the distribution of TIMP-4 and MMP-26 in endometrial tissue and uterine fluid over the menstrual cycle. Endometrial tissue was analysed with in situ hybridization and immunohistochemistry to localize mRNA and protein for TIMP-4 and MMP-26 in the same set of samples. TIMP-4 mRNA was quantified in separated stromal and epithelial cells using real-time PCR. Uterine fluid was analysed with western blotting. TIMP-4 mRNA was exclusively localized to the stroma, whereas MMP-26 mRNA was expressed by epithelial cells. TIMP-4 protein was only occasionally found in the stroma but was consistently present in granules of the apical part of luminal and glandular epithelial cells. TIMP-4, but not MMP-26, was demonstrated in uterine fluid. Thus, TIMP-4 is produced in the stroma only, secreted by stromal cells, taken up by epithelial cells, accumulated in apical granules and finally secreted to the uterine fluid. Maximal expression of MMP-26, and its strongest inhibitor TIMP-4, in the early and mid-secretory phase suggests a role during implantation. MMP-26 is stored in epithelial cells in its active form, is not released spontaneously and is controlled by TIMP-4 in both stroma and uterine fluid.
- 29 June 2006
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 12 (8) , 497-503
Open AccessEndometrial TIMP-4 mRNA is expressed in the stroma, while TIMP-4 protein accumulates in the epithelium and is released to the uterine fluid
We have previously reported that endometrial mRNA expression of both tissue inhibitors of metalloproteinase-4 (TIMP-4) and matrix metalloproteinase-26 (MMP-26) peaks in the early secretory phase, which implies a role in implantation. The objective of this study was to compare the distribution of TIMP-4 and MMP-26 in endometrial tissue and uterine fluid over the menstrual cycle. Endometrial tissue was analysed with in situ hybridization and immunohistochemistry to localize mRNA and protein for TIMP-4 and MMP-26 in the same set of samples. TIMP-4 mRNA was quantified in separated stromal and epithelial cells using real-time PCR. Uterine fluid was analysed with western blotting. TIMP-4 mRNA was exclusively localized to the stroma, whereas MMP-26 mRNA was expressed by epithelial cells. TIMP-4 protein was only occasionally found in the stroma but was consistently present in granules of the apical part of luminal and glandular epithelial cells. TIMP-4, but not MMP-26, was demonstrated in uterine fluid. Thus, TIMP-4 is produced in the stroma only, secreted by stromal cells, taken up by epithelial cells, accumulated in apical granules and finally secreted to the uterine fluid. Maximal expression of MMP-26, and its strongest inhibitor TIMP-4, in the early and mid-secretory phase suggests a role during implantation. MMP-26 is stored in epithelial cells in its active form, is not released spontaneously and is controlled by TIMP-4 in both stroma and uterine fluid.